Dr. Martens Performance degli utili passati
Criteri Il passato verificati 3/6
Gli utili di Dr. Martens sono diminuiti a un tasso medio annuo di -29.2%, mentre il settore Luxury ha visto gli utili crescere a un tasso medio annuo di 5.6%. I ricavi sono cresciuti diminuire a un tasso medio annuo di 2.3%. Il ritorno sul capitale proprio di Dr. Martens è 6.6% e ha margini netti di 3.1%.
Informazioni chiave
-29.21%
Tasso di crescita degli utili
-28.80%
Tasso di crescita dell'EPS
| Luxury Crescita del settore | 27.60% |
| Tasso di crescita dei ricavi | -2.35% |
| Rendimento del capitale proprio | 6.58% |
| Margine netto | 3.11% |
| Ultimo aggiornamento sugli utili | 29 Mar 2026 |
Aggiornamenti sulle prestazioni recenti
Articolo di analisi • May 28
We Think Dr. Martens' (LON:DOCS) Solid Earnings Are Understated
Investors signalled that they were pleased with Dr. Martens plc's ( LON:DOCS ) most recent earnings report. Looking...Articolo di analisi • Jun 15
Some Investors May Be Willing To Look Past Dr. Martens' (LON:DOCS) Soft Earnings
Dr. Martens plc's ( LON:DOCS ) stock was strong despite it releasing a soft earnings report last week. Our analysis...Recent updates
Aggiornamento della narrazione • Jun 29
DOCS: Future Returns Will Depend On Margins And Long Term Sustainability Partnership
Analysts have trimmed their price target on Dr. Martens, reflecting slightly lower fair value assumptions alongside modestly reduced projections for revenue growth, profit margins and future P/E multiples in their models. What’s in the News for Dr. Martens No recent news items for Dr. Martens are available from the specified primary sources at this time.
Aggiornamento della narrazione • Jun 15
DOCS: Future Returns Will Rely On Steady Margins And Supportive Long Term Assumptions
Analysts have adjusted their price target on Dr. Martens, reflecting updated views on revenue growth, profit margins, the discount rate and future P/E assumptions. Together, these factors point to a refined estimate of the stock's underlying value in £ terms.Aggiornamento della narrazione • Jun 01
DOCS: Future Returns Will Rely On Sustained Margins And Supportive Long Term Assumptions
Analysts have adjusted their price target on Dr. Martens to reflect updated assumptions around the discount rate, revenue growth, profit margin, and future P/E. This has led to a revised view of the stock's valuation in £ terms.Articolo di analisi • May 28
We Think Dr. Martens' (LON:DOCS) Solid Earnings Are Understated
Investors signalled that they were pleased with Dr. Martens plc's ( LON:DOCS ) most recent earnings report. Looking...Aggiornamento della narrazione • May 13
DOCS: Future Returns Will Depend On Steady Margins And Long Term Assumptions
Analysts have adjusted their price views on Dr. Martens, reflecting updated assumptions around discount rates, modestly different revenue growth and profit margin expectations, and a slightly altered future P/E multiple. Together, these factors feed into a refreshed £1.41 fair value estimate.Aggiornamento della narrazione • Apr 28
DOCS: Future Returns Will Rely On Profit Focus And Stable Long Term Assumptions
Analysts have adjusted their price targets on Dr. Martens upward to £1.41, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E that are broadly in line with previous estimates but fine tuned to current views. Valuation Changes Fair Value: Modelled fair value remains at £1.41, with no change from the previous estimate.Aggiornamento della narrazione • Apr 11
DOCS: Future Returns Will Rely On Profit Focus And Flat 2026 Revenue
Analysts have trimmed their price target on Dr. Martens to £1.41 from £1.41. They point to slightly higher assumed discount rates and modestly different revenue growth and profit margin expectations that keep the overall valuation level broadly unchanged.Aggiornamento della narrazione • Mar 27
DOCS: Future Returns Will Rely On Profit Focus And Flat 2026 Revenue
Analysts have trimmed their fair value assumptions slightly, nudging the implied P/E closer to £19.95 and reflecting small updates to discount rate, revenue growth and profit margin expectations for Dr. Martens. What's in the News Issued earnings guidance for fiscal 2026 with revenue expected to be broadly flat on a constant currency basis as the company focuses on the quality of revenue and profitability (company guidance).Aggiornamento della narrazione • Mar 13
DOCS: Future Returns Will Depend On Profit-Led Flat Revenue Guidance In 2026
Analysts have nudged their price target for Dr. Martens higher to £1.41, citing modest adjustments to assumptions about the discount rate, revenue, profit margin and future P/E in their updated models. What's in the News Dr. Martens issued earnings guidance for fiscal 2026, indicating that revenue on a constant currency basis is expected to be broadly flat as the company focuses on the quality of revenue and profitability (company guidance).Aggiornamento della narrazione • Feb 27
DOCS: Future Returns Will Depend On Prioritising Profitability Over Near Term Revenue Expansion
Analysts have lifted their price target for Dr. Martens to £1.41, reflecting slightly revised assumptions for discount rate, revenue growth, profit margin and future P/E that collectively point to a modestly improved risk and earnings profile. What's in the News Dr. Martens issued earnings guidance for fiscal 2026, indicating that revenue on a constant currency basis is expected to be broadly flat as the company focuses on the quality of revenue and profitability (company guidance).Articolo di analisi • Feb 12
Dr. Martens' (LON:DOCS) Dividend Will Be £0.0085
Dr. Martens plc ( LON:DOCS ) has announced that it will pay a dividend of £0.0085 per share on the 9th of April. This...Aggiornamento della narrazione • Feb 10
DOCS: Future Returns Will Depend On Expanding Reclaimed Leather Sustainability Collaboration
Analysts have adjusted their price targets for Dr. Martens modestly, reflecting revised assumptions around the discount rate, expected revenue growth, profit margins and a higher future P/E multiple, which together temper the valuation outlook while still supporting a measured premium on earnings. What's in the News Dr. Martens and materials company Gen Phoenix are marking four consecutive seasons of collaboration, extending their work with reclaimed leather under the Genix Nappa line.Aggiornamento della narrazione • Jan 26
DOCS: Future Returns Will Rely On Reclaimed Leather Sustainability Partnership
Analysts have adjusted their price targets for Dr. Martens, reflecting updated assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple. Taken together, these factors point to a revised view of the shares' potential value, even though the fair value estimate remains at £1.41.Aggiornamento della narrazione • Jan 11
DOCS: Future Returns Will Rely On Margins And Long Term Sustainability Partnership
Analysts have made a modest trim to their price target on Dr. Martens, reflecting slightly adjusted assumptions around discount rates, revenue growth, profit margins and future P/E, while still seeing the shares as aligned with an updated fair value of 0.8x. What's in the News Dr. Martens and Gen Phoenix mark four consecutive seasons of working together on reclaimed leather products under the Genix Nappa line, highlighting a multi year partnership rather than a short pilot or capsule approach (Key Developments).Aggiornamento della narrazione • Dec 26
DOCS: Future Returns Will Depend On Margin Execution And Sustainability Delivery
Analysts have modestly adjusted their price target on Dr. Martens to 75 GBp, reflecting slightly higher long term revenue growth and profit margin assumptions while maintaining a broadly Neutral stance. Analyst Commentary Analyst commentary around Dr. Martens has remained measured, with the latest work reiterating a Neutral stance and a 75 GBp price target, signaling limited upside in the near term.Aggiornamento della narrazione • Dec 12
DOCS: Modest Upside Outlook Will Hinge On Margin Recovery And Sustainability Expansion
The analyst price target for Dr. Martens has been modestly raised to £0.80 from £0.75, as analysts factor in slightly stronger expectations for revenue growth, profit margins, and future earnings multiples, while still maintaining a cautious overall stance. Analyst Commentary Recent Street research has reinforced a measured stance on Dr. Martens, with coverage reinstated at a neutral rating and a price target that sits below longer term historical trading levels.Articolo di analisi • Dec 01
Shareholders Should Be Pleased With Dr. Martens plc's (LON:DOCS) Price
Dr. Martens plc's ( LON:DOCS ) price-to-earnings (or "P/E") ratio of 48.9x might make it look like a strong sell right...Articolo di analisi • Nov 04
Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 26% Above Its Share Price
Key Insights The projected fair value for Dr. Martens is UK£1.13 based on 2 Stage Free Cash Flow to Equity Dr. Martens...
Aggiornamento della narrazione • Oct 08
Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26
Analysts have raised their price target on Dr. Martens from £0.80 to £1.12 per share, citing expectations that 2025 will mark a turning point for the company and stating that market valuations do not yet reflect its long-term growth potential. Analyst Commentary Market watchers have offered mixed insights following the recent upgrade and price target increase for Dr. Martens.Articolo di analisi • Aug 26
Returns On Capital Signal Tricky Times Ahead For Dr. Martens (LON:DOCS)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Aggiornamento della narrazione • Aug 19
Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26
Despite a notable downgrade in forecast revenue growth and a higher projected future P/E, analysts have nonetheless raised Dr. Martens’ consensus price target from £0.898 to £0.952. What's in the News The Board of Dr. Martens proposed a final dividend of 1.70 pence, maintaining the total dividend for fiscal year 2025 at 2.55 pence, equal to the prior year, pending shareholder approval.Articolo di analisi • Aug 05
Is Dr. Martens plc (LON:DOCS) Trading At A 29% Discount?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Dr. Martens fair value estimate is UK£1.09 Dr. Martens...Articolo di analisi • Jun 18
Dr. Martens (LON:DOCS) Has Announced That It Will Be Increasing Its Dividend To £0.017
Dr. Martens plc's ( LON:DOCS ) dividend will be increasing from last year's payment of the same period to £0.017 on 8th...Articolo di analisi • Jun 15
Some Investors May Be Willing To Look Past Dr. Martens' (LON:DOCS) Soft Earnings
Dr. Martens plc's ( LON:DOCS ) stock was strong despite it releasing a soft earnings report last week. Our analysis...Articolo di analisi • Apr 15
Dr. Martens (LON:DOCS) May Have Issues Allocating Its Capital
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Nuova narrazione • Mar 14
Cost Savings Ahead Of Schedule Will Improve Profitability By FY '26
Strategic focus on premium positioning, demand planning, and cost reductions aims to enhance revenue, margins, and profitability.Articolo di analisi • Dec 06
Earnings Tell The Story For Dr. Martens plc (LON:DOCS) As Its Stock Soars 27%
Dr. Martens plc ( LON:DOCS ) shareholders would be excited to see that the share price has had a great month, posting a...Articolo di analisi • Dec 01
Dr. Martens plc (LON:DOCS) Half-Yearly Results: Here's What Analysts Are Forecasting For This Year
The investors in Dr. Martens plc 's ( LON:DOCS ) will be rubbing their hands together with glee today, after the share...Articolo di analisi • Sep 21
Benign Growth For Dr. Martens plc (LON:DOCS) Underpins Stock's 30% Plummet
The Dr. Martens plc ( LON:DOCS ) share price has fared very poorly over the last month, falling by a substantial 30...Articolo di analisi • Aug 20
Is There An Opportunity With Dr. Martens plc's (LON:DOCS) 45% Undervaluation?
Key Insights Dr. Martens' estimated fair value is UK£1.31 based on 2 Stage Free Cash Flow to Equity Dr. Martens...Articolo di analisi • Jul 20
Dr. Martens (LON:DOCS) Has Some Way To Go To Become A Multi-Bagger
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Articolo di analisi • Jun 19
There May Be Some Bright Spots In Dr. Martens' (LON:DOCS) Earnings
The market was pleased with the recent earnings report from Dr. Martens plc ( LON:DOCS ), despite the profit numbers...Articolo di analisi • May 21
Dr. Martens plc's (LON:DOCS) Price Is Right But Growth Is Lacking After Shares Rocket 27%
Dr. Martens plc ( LON:DOCS ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...Articolo di analisi • Mar 27
The Trend Of High Returns At Dr. Martens (LON:DOCS) Has Us Very Interested
If you're looking for a multi-bagger, there's a few things to keep an eye out for. In a perfect world, we'd like to see...Articolo di analisi • Mar 06
Dr. Martens (LON:DOCS) Has A Somewhat Strained Balance Sheet
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Articolo di analisi • Feb 08
Dr. Martens plc's (LON:DOCS) Intrinsic Value Is Potentially 57% Above Its Share Price
Key Insights The projected fair value for Dr. Martens is UK£1.32 based on 2 Stage Free Cash Flow to Equity Dr. Martens...Articolo di analisi • Jan 21
Dr. Martens plc's (LON:DOCS) Business And Shares Still Trailing The Market
With a price-to-earnings (or "P/E") ratio of 6.9x Dr. Martens plc ( LON:DOCS ) may be sending very bullish signals at...Articolo di analisi • Jan 03
Dr. Martens' (LON:DOCS) Dividend Will Be £0.0156
Dr. Martens plc ( LON:DOCS ) has announced that it will pay a dividend of £0.0156 per share on the 2nd of February...Articolo di analisi • Dec 13
Dr. Martens (LON:DOCS) Will Pay A Dividend Of £0.0156
Dr. Martens plc's ( LON:DOCS ) investors are due to receive a payment of £0.0156 per share on 2nd of February. This...Ripartizione dei ricavi e delle spese
Ripartizione dei ricavi e delle spese
Come Dr. Martens guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storico di utili e ricavi
| Data | Ricavi | Utili | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 29 Mar 26 | 765 | 24 | 366 | 0 |
| 29 Dec 25 | 775 | 20 | 370 | 0 |
| 28 Sep 25 | 785 | 15 | 375 | 0 |
| 28 Jun 25 | 786 | 10 | 377 | 0 |
| 30 Mar 25 | 788 | 5 | 378 | 0 |
| 30 Dec 24 | 797 | 17 | 376 | 0 |
| 29 Sep 24 | 806 | 29 | 374 | 0 |
| 29 Jun 24 | 842 | 49 | 376 | 0 |
| 31 Mar 24 | 877 | 69 | 378 | 0 |
| 31 Dec 23 | 927 | 86 | 386 | 0 |
| 30 Sep 23 | 978 | 103 | 395 | 0 |
| 30 Jun 23 | 989 | 116 | 384 | 0 |
| 31 Mar 23 | 1,000 | 129 | 373 | 0 |
| 31 Dec 22 | 979 | 153 | 372 | 0 |
| 30 Sep 22 | 957 | 177 | 371 | 0 |
| 30 Jun 22 | 933 | 179 | 343 | 0 |
| 31 Mar 22 | 908 | 181 | 316 | 0 |
| 31 Dec 21 | 867 | 118 | 310 | 0 |
| 30 Sep 21 | 825 | 54 | 304 | 0 |
| 30 Jun 21 | 799 | 44 | 276 | 0 |
| 31 Mar 21 | 773 | 35 | 248 | 0 |
| 31 Dec 20 | 747 | 61 | 219 | 0 |
| 30 Sep 20 | 722 | 87 | 191 | 0 |
| 30 Jun 20 | 697 | 81 | 204 | 0 |
| 31 Mar 20 | 672 | 75 | 217 | 0 |
| 31 Mar 19 | 454 | 17 | 124 | 0 |
| 31 Mar 18 | 349 | -6 | 94 | 0 |
| 31 Mar 17 | 291 | -11 | 75 | 0 |
| 31 Mar 16 | 232 | -12 | 56 | 0 |
Guadagni di qualità: DOCS ha un grande una tantum perdita di £16.3M che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 29th March, 2026.
Margine di profitto in crescita: Gli attuali margini di profitto netti di DOCS (3.1%) DOCS sono più alti rispetto allo scorso anno (0.6%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: Gli utili di DOCS sono diminuiti del 29.2% all'anno negli ultimi 5 anni.
Accelerare la crescita: La crescita degli utili di DOCS nell'ultimo anno ( 413.1% ) supera la media quinquennale ( -29.2% all'anno).
Guadagni vs Settore: La crescita degli utili DOCS nell'ultimo anno ( 413.1% ) ha superato la percentuale del settore Luxury -0.3%.
Rendimento del capitale proprio
ROE elevato: Il Return on Equity ( 6.6% ) di DOCS è considerato basso.
Rendimento delle attività
Rendimento del capitale investito
Scoprire le aziende con forti performance passate
Analisi aziendale e situazione dei dati finanziari
| Dati | Ultimo aggiornamento (ora UTC) |
|---|---|
| Analisi dell'azienda | 2026/07/05 21:26 |
| Prezzo dell'azione a fine giornata | 2026/07/03 00:00 |
| Utili | 2026/03/29 |
| Utili annuali | 2026/03/29 |
Fonti dei dati
I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
| Pacchetto | Dati | Tempistica | Esempio Fonte USA * |
|---|---|---|---|
| Dati finanziari della società | 10 anni |
| |
| Stime di consenso degli analisti | +3 anni |
|
|
| Prezzi di mercato | 30 anni |
| |
| Proprietà | 10 anni |
| |
| Gestione | 10 anni |
| |
| Sviluppi principali | 10 anni |
|
* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.
Modello di analisi e Snowflake
I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; disponiamo inoltre di guide su come utilizzare i nostri report e di tutorial su Youtube.
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali
Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.
Fonti analitiche
Dr. Martens plc è coperta da 13 analisti. 5 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
| Analista | Istituzione |
|---|---|
| Richard Taylor | Barclays |
| Anne Critchlow | Berenberg |
| David Roux | BofA Global Research |